Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes



Rating:

Share or cite this content

Citations should be made in the following way:
A. Jee (Sydney (NSW), Australia), I. Stewart (London, United Kingdom), P. Youssef (Sydney (NSW), Australia), S. Adelstein (Sydney (NSW), Australia), D. Lai (Sydney (NSW), Australia), S. Hua (Sydney (NSW), Australia), W. Stevens (Melbourne (VIC), Australia), S. Proudman (Adelaide (SA), Australia), G. Ngian (Melbourne (VIC), Australia), I. Glaspole (Melbourne (VIC), Australia), Y. Moodley (Perth (WA), Australia), J. Bleasel (Sydney (NSW), Australia), S. Macansh (Sydney (NSW), Australia), M. Nikpour (Melbourne (VIC), Australia), J. Sahhar (Melbourne (VIC), Australia), T. Corte (Sydney (NSW), Australia), .. On Behalf Of The Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, And Associated Investigators (Various, Australia). Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study. 2976

Member's Comments

No comment yet.

Related content which might interest you: PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018 Year: 2019 Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Late Breaking Abstract - A single centre observational study of inflammatory biomarkers in Covid 19 and clinically important outcomes Source: Virtual Congress 2021 – Back to infection basics Year: 2021 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Development of a new prognosis index (BODS) in patients with COPD:a prospective cohort study Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Persistent lung abnormalities versus established fibrosis: a prospective study of COVID-19 follow-up Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013 Source: Eur Respir J , 49 (2) 1601290; DOI: 10.1183/13993003.01290-2016 Year: 2017 A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 1-year prospective study in severe COPD patients: marker of inflammation, lung function and radiologic evaluation Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Characteristics and clinical management of IPF patients in Spain: prospective, observational, multicentric study (OASIS study). Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - 1-year radiological, functional and quality-of-life outcomes in patients with SARS-CoV-2 pneumonia: A prospective observational study. Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Early symptoms in suspected lung cancer: a prospective cohort study Source: Eur Respir J 2001; 18: Suppl. 33, 64s Year: 2001 Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study) Source: Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020 Year: 2021 Late Breaking Abstract - Identification of obstructive lung disease in Austrian pharmacies - a multi-site, cross-sectional case finding study Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021 Year: 2022 CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020 Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018